Jonathan L Slaughter, MD, MPH
@jonathanlslaug1
Father, Neonatologist, Epidemiologist- working to improve neonatal outcomes #comparativeeffectiveness #pharmacoepidemiology @nchfordocs
ID: 1001959422049095680
https://scholar.google.com/citations?user=W-G-K9oAAAAJ&hl=en 30-05-2018 22:51:56
403 Tweet
421 Followers
358 Following
Publication alert: infants with BPD develop rapid tolerance to furosemide diuresis. Consider the possibility of diminishing returns during prolonged courses! Open-access to the details in JournalofPediatrics through 2/10/24: authors.elsevier.com/a/1iIQJ55Cs8O8v #neoebm #neotwitter #foamneo
Brian King Dinushan Kaluarachchi Evidence-Based Neo Exactly. Not treatment was randomised, but “the intention of the clinical team”: PDA potential causal factor versus indicator of immaturity. Clinical equipoise essential! Proven successful given an open label percentage of only 0.7%.
Brett J. Manley 🤷🏼♂️ Naveed Durrani. MD. FCPS. FRCPCH Matthew Kielt, MD The BPD Collaborative Even for off-label drugs we need to focus on the evidence more to guide clinicians through consensus (known risks vs potential benefits). A paper our peds pharmacoepi #ISPE group coauthored last year: onlinelibrary.wiley.com/doi/10.1002/pd… #neotwitter #pharmacoepidemiology #neoEBM
Young Investigator Winner Dr. Gentle Samuel J Gentle UAB Department of Pediatrics Great work in Neo Telehealth! Amy Hair MD Ravi Mangal Patel
Jonathan L Slaughter, MD, MPH NICUofThings Souvik Mitra 100% - even before transfer for an invasive procedure I find it's typically phrased as "they need it closed" as opposed to "it's something we could consider but aren't certain it will help, and could have complications/side effects".